Incidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study
Frontiers in Public Health · 2025
DOI: 10.3389/fpubh.2025.1690348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Siwei Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Hospital Affiliated to Southern Univer…. Hauptthemen laut MEDLINE: Papillomavirus Infections, HIV Infections, Persistent Infection, Papillomaviridae. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Background
Although the 9-valent HPV vaccine (9v-HPV) has been approved for males in China, it has received limited public attention. This study aimed to explore the incidence and persistence of different HPV types in HIV-related males and emphasize the importance of vaccination.
Methods
A cohort of 758 male patients with multiple HPV detection (≥3) from 2018 to 2023 in our hospital were enrolled for statistical analysis, including 113 Men who have Sex with Men (MSM) patients. HIV and HPV infection statuses were confirmed respectively by ELISA, PCR, WB and nucleic acid kit.
Results
Statistical analysis revealed that the incidence of 9v-HPV-covered high-risk (HR) HPV infections were 68.1% (HIV + total males), 43.2% (HIV − total males), 67.6% (HIV + MSM) and 42.2% (HIV − MSM). HPV persistence was significantly prolonged in HIV + patients than HIV − cases ( p < 0.001). Markov model demonstrated that HIV increased incidence risks of HPV52, 58, 45, 35, 39, 51, 59, 68, 66, 73, 82, 81 and reduced the clearance rates of HPV16, 18, 6, 11, 58, 33, 31, 56 in males.
Discussion
These findings highlight the increased burden of HPV infection among HIV + individuals. Timely vaccination will benefit males by preventing HPV infection and consequently reducing the associated disease burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
- Department of Endodontics, The First Affiliated Hospital of Harbin Medical University, School of Stomatology, Harbin Medical University, Harbin, China.
- School of Public Health, Guangzhou Medical University, Guangzhou, China.
- Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
- Department of Dermatology and Venereology, The Third People's Hospital of Shenzhen, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
- Department of Microbiology, Harbin Medical University, Harbin, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Zhang, S., Liu, H., Huang, Z., Duan, S., Zhang, Y., Li, Y., Chu, W., Wang, Y., Yang, R., & Wei, L. (2025). Incidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1690348
Vancouver
Zhang S, Liu H, Huang Z, Duan S, Zhang Y, Li Y, et al. Incidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1690348
BibTeX
@article{Zhang2025,
author = {Zhang, Siwei and Liu, Huan and Huang, Zhiyan and Duan, Siyu and Zhang, Yuting and Li, Yanjing and Chu, Wenzhu and Wang, Yan and Yang, Rongqing and Wei, Lanlan},
title = {Incidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study},
journal = {Frontiers in Public Health},
year = {2025},
doi = {10.3389/fpubh.2025.1690348}
}
EUVIMED